H.C. Wainwright analyst Raghuram Selvaraju raised the firm’s price target on Rhythm Pharmaceuticals (RYTM) to $110 from $100 and keeps a Buy rating on the shares. The firm expects near-term expansion of Imcivree’s label into the population of patients with hypothalamic obesity in the wake of positive results from the pivotal Phase 3 TRANSCEND trial reported in early April. Rhythm could achieve sustainable profitability in 2027, depending upon the progression of its clinical-stage programs, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RYTM:
- Rhythm Pharmaceuticals price target raised to $142 from $135 at Citizens JMP
- Rhythm Pharmaceuticals: Strong Commercial Strategy and Promising Market Potential for aHO Treatment Justifies Buy Rating
- Rhythm Pharmaceuticals price target raised to $122 from $109 at Morgan Stanley
- Rhythm Pharmaceuticals: Buy Rating Backed by FDA Priority Review and Positive Phase 3 Results
- Rhythm Pharmaceuticals announces FDA acceptance of sNDA for setmelanotide